Ivosidenib (** Tibsovo (brand name); ivo)

Targeted Therapy

Not submitted to EMA

Not funded 2 Clinical Trials

Description

Ivosidenib is approved for the treatment of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (AML) and has shown efficacy in certain solid tumors, including some cases of colorectal cancer. However, its use in colorectal cancer remains investigational and limited to clinical trials evaluating its role in specific subtypes.

Mechanism of Action

Ivosidenib is a selective inhibitor of mutant isocitrate dehydrogenase-1 (IDH1) and acts by inhibiting the production of 2-hydroxyglutarate, which leads to decreased DNA hypermethylation and cell differentiation.

Side Effects

Fatigue; nausea; diarrhea; vomiting; constipation; abdominal pain; decreased appetite; rash; myalgia; arthralgia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06593548 Phase 2

Not yet recruiting

Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer

China

NCT03155620 Phase 2

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

United States, Australia, Canada, Puerto Rico

Quick Info

Brand Name	** Tibsovo (brand name); ivo
Category	Targeted Therapy
EMA Status	Not submitted to EMA
Spain Access	Not funded
Clinical Trials	2

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.